Matthijs M. Tibben
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 20, 2025
Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof-of-Concept Study with Alectinib.
Journal: Clinical pharmacology and therapeutics
Published: July 21, 2025
Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient-A Case Report.
Journal: Cancer reports (Hoboken, N.J.)
Published: February 10, 2025
Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors.
Journal: Oncology and therapy
Published: February 05, 2025
An ultra-sensitive liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 2H6-alectinib and alectinib in human plasma to support a microtracer food-effect trial.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Published: December 05, 2024
Brain Exposure to the Macrocyclic ALK Inhibitor Zotizalkib is Restricted by ABCB1, and Its Plasma Disposition is Affected by Mouse Carboxylesterase 1c.
Journal: Molecular pharmaceutics
Published: September 23, 2024
Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice.
Journal: Molecular pharmaceutics
Published: February 29, 2024
Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in mice.
Journal: International journal of pharmaceutics
Published: October 09, 2023
Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.
Journal: Journal of clinical pharmacology
Published: May 23, 2023
Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: May 05, 2022
A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: April 04, 2022
Last Updated: 09/26/2026